Angiotensin

Summary

Angiotensin (CHEMBL2391146) is a phase-3 clinical-stage protein targeting MAS1 and AGTR2; indicated across 3 conditions including hypertensive disorder and kidney disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Targets: 2 (MAS1, AGTR2)
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 956.1 Da · C43H65N13O12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2391146
Name	Angiotensin
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	15171724
Molecular formula	C43H65N13O12
Molecular weight	956.1
InChIKey	JSQIKKVBLLHQSQ-AWJAZODESA-N

SMILES: C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N

IUPAC name: (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid

Also known as: Angiotensin, ANGIOTENSIN, US10370388, Compound Angiotensin

Patent coverage: 478 distinct patent families (703 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MAS1	MAS1	Agonist	7.31		P04201
AGTR2	AT2 receptor	Agonist	6.61	0.1%	P50052

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Type-2 angiotensin II receptor.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
AGTR2	9.89	IC50	0.13	nM	CHEMBL_ACT_13336212
AGTR2	9.05	Ki	0.9	nM	CHEMBL_ACT_27725318
AGTR2	8.74	IC50	1.8	nM	CHEMBL_ACT_27725315

Target pathways

Aggregated over 2 target gene(s): MAS1, AGTR2.

Top Reactome pathways

7 total, by targets touching each:

Pathway	Targets	Genes
Peptide ligand-binding receptors	2	AGTR2, MAS1
Signal Transduction	1	AGTR2
Signaling by GPCR	1	AGTR2
Class A/1 (Rhodopsin-like receptors)	1	AGTR2
GPCR downstream signalling	1	AGTR2
G alpha (i) signalling events	1	AGTR2
GPCR ligand binding	1	AGTR2

Dominant GO biological processes

GO term	Targets
angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressure	2
G protein-coupled receptor signaling pathway	2
signal transduction	2
angiotensin-activated signaling pathway	2
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
positive regulation of canonical NF-kappaB signal transduction	1
regulation of inflammatory response	1
phospholipase C-activating angiotensin-activated signaling pathway	1
blood vessel remodeling	1
regulation of systemic arterial blood pressure by circulatory renin-angiotensin	1
brain renin-angiotensin system	1
inflammatory response	1
cell surface receptor signaling pathway	1
G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger	1
brain development	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	3	MONDO:0005044	EFO:0000537
kidney disorder	3	MONDO:0005240	EFO:0003086
chronic kidney disease	3	MONDO:0005300	MONDO:0024327

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00863252	PHASE4	COMPLETED	Mycophenolate Mofetil for IgA Nephropathy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

19 molecules share ≥1 primary target. Top 19 by shared-target count:

Molecule	Source	Status	Shared targets
LOSARTAN	ChEMBL + PubChem	Phase 4 (approved)	AGTR2
OLMESARTAN MEDOXOMIL	ChEMBL + PubChem	Phase 4 (approved)	AGTR2
ANGIOTENSIN II	ChEMBL	Phase 4 (approved)	AGTR2
AZILSARTAN MEDOXOMIL	ChEMBL	Phase 4 (approved)	AGTR2
BENAZEPRIL	ChEMBL	Phase 4 (approved)	AGTR2
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	AGTR2
DICLOFENAC	ChEMBL	Phase 4 (approved)	AGTR2
IRBESARTAN	ChEMBL	Phase 4 (approved)	AGTR2
MICONAZOLE	ChEMBL	Phase 4 (approved)	AGTR2
SARALASIN	ChEMBL	Phase 4 (approved)	AGTR2
TELMISARTAN	ChEMBL	Phase 4 (approved)	AGTR2
OLMESARTAN	ChEMBL + PubChem	Phase 3 (approved)	AGTR2
CANDESARTAN	ChEMBL	Phase 3	AGTR2
FORASARTAN	ChEMBL	Phase 2	AGTR2
OLODANRIGAN	ChEMBL	Phase 2	AGTR2
PRATOSARTAN	ChEMBL	Phase 2	AGTR2
TASOSARTAN	ChEMBL	Phase 2	AGTR2
Amiloride	PubChem	Approved	AGTR2
Anagrelide	PubChem	Approved	AGTR2